AZN - Analyzing AstraZeneca In Comparison To Competitors In Pharmaceuticals Industry | Benzinga
Amidst today's fast-paced and highly competitive business environment, it is crucial for investors and industry enthusiasts to conduct comprehensive company evaluations. In this article, we will delve into an extensive industry comparison, evaluating AstraZeneca (NASDAQ:AZN) in comparison to its major competitors within the Pharmaceuticals industry. By analyzing critical financial metrics, market position, and growth potential, our objective is to provide valuable insights for investors and offer a deeper understanding of company's performance in the industry.
AstraZeneca Background
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.
| Company | P/E | P/B | P/S | ROE | EBITDA (in billions) | Gross Profit (in billions) | Revenue Growth |
|---|---|---|---|---|---|---|---|
| AstraZeneca PLC | |||||||
| 33.60 | |||||||
| 5.29 | |||||||
| 4.40 | |||||||
| 3.68% | |||||||
| $3.33 | |||||||
| $9.4 | |||||||
| 4.64% | |||||||
| Eli Lilly and Co | |||||||
| 105.80 | |||||||
| 49.41 | |||||||
| 16.45 | |||||||
| -0.52% | |||||||
| $0.96 | |||||||
| $7.64 | |||||||
| 36.84% | |||||||
| Novo Nordisk A/S | |||||||
| 40.04 | |||||||
| 32.11 | |||||||
| 14.07 | |||||||
| 24.5% | |||||||
| $32.76 | |||||||
| $49.02 | |||||||
| 28.89% | |||||||
| Johnson & Johnson | |||||||
| 29.09 | |||||||
| 5.24 | |||||||
| 4.11 | |||||||
| 35.56% | |||||||
| $7.24 | |||||||
| $14.74 | |||||||
| 6.78% | |||||||
| Merck & Co Inc | |||||||
| 57.98 | |||||||
| 6.41 | |||||||
| 4.48 | |||||||
| 11.87% | |||||||
| $6.95 | |||||||
| $11.7 | |||||||
| 6.71% | |||||||
| Novartis AG | |||||||
| 25.20 | |||||||
| 5.24 | |||||||
| 3.79 | |||||||
| 3.91% | |||||||
| $4.88 | |||||||
| $8.97 | |||||||
| 12.14% | |||||||
| Pfizer Inc | |||||||
| 15.65 | |||||||
| 1.67 | |||||||
| 2.39 | |||||||
| -2.43% | |||||||
| $-1.1 | |||||||
| $3.96 | |||||||
| -41.55% | |||||||
| Bristol-Myers Squibb Co | |||||||
| 12.97 | |||||||
| 3.58 | |||||||
| 2.39 | |||||||
| 6.32% | |||||||
| $4.85 | |||||||
| $8.46 | |||||||
| -2.25% | |||||||
| Zoetis Inc | |||||||
| 38.59 | |||||||
| 17.13 | |||||||
| 10.50 | |||||||
| 12.28% | |||||||
| $0.9 | |||||||
| $1.51 | |||||||
| 7.44% | |||||||
| GSK PLC | |||||||
| 9.78 | |||||||
| 4.54 | |||||||
| 2 | |||||||
| 11.34% | |||||||
| $2.55 | |||||||
| $5.88 | |||||||
| 4.06% | |||||||
| Takeda Pharmaceutical Co Ltd | |||||||
| 33.55 | |||||||
| 0.90 | |||||||
| 1.55 | |||||||
| -0.69% | |||||||
| $202.28 | |||||||
| $699.51 | |||||||
| 4.07% | |||||||
| Viatris Inc | |||||||
| 6.51 | |||||||
| 0.57 | |||||||
| 0.77 | |||||||
| 1.59% | |||||||
| $1.22 | |||||||
| $1.69 | |||||||
| -3.34% | |||||||
| Dr Reddy's Laboratories Ltd | |||||||
| 17.71 | |||||||
| 3.56 | |||||||
| 3.38 | |||||||
| 5.94% | |||||||
| $23.28 | |||||||
| $40.37 | |||||||
| 9.11% | |||||||
| Jazz Pharmaceuticals PLC | |||||||
| 146.12 | |||||||
| 2.19 | |||||||
| 2.23 | |||||||
| 4.19% | |||||||
| $0.33 | |||||||
| $0.87 | |||||||
| 3.35% | |||||||
| Corcept Therapeutics Inc | |||||||
| 33.99 | |||||||
| 6.07 | |||||||
| 6.84 | |||||||
| 7.06% | |||||||
| $0.03 | |||||||
| $0.12 | |||||||
| 21.5% | |||||||
| Amphastar Pharmaceuticals Inc | |||||||
| 22.28 | |||||||
| 4.59 | |||||||
| 5 | |||||||
| 8.31% | |||||||
| $0.09 | |||||||
| $0.11 | |||||||
| 50.3% | |||||||
| Average | |||||||
| 39.68 | |||||||
| 9.55 | |||||||
| 5.33 | |||||||
| 8.62% | |||||||
| $19.15 | |||||||
| $56.97 | |||||||
| 9.6% |